All Articles
Crystal Dugger offers insight on the business philosophy of Sarah Cannon (HCA) and the elements of a successful program.
Read More ›
Crystal Dugger suggests why it might be challenging to get key people onboard and suggests how to change that. Read More ›
Crystal Dugger warns administrators to avoid “scope creep” by having their navigators take on too many tasks; she says the navigator’s focus must always be on the patient.
Read More ›
Crystal Dugger stresses the necessity of standardizing and quantifying the value of a navigation program to the institution.
Read More ›
What does it take to sustain a navigation program for years to come? Crystal Dugger lists the most important ones for long-term sustainability. Read More ›
On February 15, 2019, the US Food and Drug Administration (FDA) approved the immunotherapy agent pembrolizumab (Keytruda; Merck) for the adjuvant treatment of patients with resected stage III melanoma. Read More ›
On February 12, 2019, the US Food and Drug Administration (FDA) granted approval for daratumumab (Darzalex; Janssen), a CD38-directed antibody, to be given in a split-dosing regimen to patients with multiple myeloma (MM). Read More ›